OncoMatch/Clinical Trials/NCT07335081

ctDNA in HER2+ EBC Neoadjuvant Treatment

Is NCT07335081 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including pyrotinib and pertuzumab for breast cancer.

Phase 2RecruitingShanghai Jiao Tong University School of MedicineNCT07335081Data as of May 2026

Treatment: pyrotinib · pertuzumab · trastuzumab · docetaxel — This study is a randomized, open-label, multicenter clinical study for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer, aiming to compare the peripheral blood ctDNA clearance of neoadjuvant pyrotinib + trastuzumab + docetaxel and pertuzumab + trastuzumab + docetaxel for one course and to evaluate the therapeutic effectiveness of four courses of neoadjuvant therapy

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: HER2 (ERBB2) overexpression

Disease stage

Required: Stage II, III

Stage II-III HER2+ breast cancer (primary diameter >2cm)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

intact bone marrow function

Kidney function

intact renal function

Liver function

intact hepatic function

Cardiac function

baseline left ventricular ejection fraction (LVEF) ≥ 55% measured by echocardiography

Intact renal, hepatic, bone marrow and cardiac functions including baseline left ventricular ejection fraction (LVEF) ≥ 55% measured by echocardiography

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify